Skip to main content
Fresenius SE & Co. KGaA logo

Fresenius SE & Co. KGaA — Investor Relations & Filings

Ticker · FRE ISIN · DE0005785604 LEI · XDFJ0CYCOO1FXRFTQS51 F Human health and social work activities
Open in API
Filings indexed 1,397 across all filing types
Latest filing 2010-11-05 Director's Dealing
Country DE Germany
Listing F FRE

About Fresenius SE & Co. KGaA

https://www.fresenius.com/

Fresenius SE & Co. KGaA is a global healthcare company that provides system-critical products and services for leading therapies for the care of critically and chronically ill patients. The company's portfolio encompasses a wide range of products and services for dialysis, hospitals, and outpatient medical care. Key offerings include intravenously administered generic drugs, biopharmaceuticals, biosimilars, clinical nutrition, and infusion therapies. Additionally, the company operates a large network of private hospitals and outpatient centers. Through its strategic investment in Fresenius Medical Care, it is a leading global provider of products and services for individuals with renal diseases.

Recent filings

Filing Released Lang Actions
DGAP-DD: Fresenius SE english
Director's Dealing Classification · 100% confidence The document explicitly contains the header "Directors’ Dealings" and details transactions made by a person performing managerial responsibilities ("Rainer Baule, Member of a managing body"). It reports the exercise of stock options and sale of shares, which falls directly under the definition of insider trading or director transactions. This corresponds precisely to the 'Director's Dealing' category.
2010-11-05 English
Q3 Report 2010
Interim / Quarterly Report Classification · 100% confidence The document is a 'Quarterly Financial Report' for the Fresenius Group covering the 1st to 3rd quarters of 2010. It contains comprehensive financial statements (income, cash flow, balance sheet), segment reporting, and management discussion and analysis. It is not an earnings release (which would be a summary) nor a report publication announcement (as it contains the full report content). Therefore, it is classified as an Interim/Quarterly Report. 9M 2010
2010-11-05 German
DGAP-DD: Fresenius SE english
Director's Dealing Classification · 100% confidence The document explicitly uses the header "Directors’ Dealings" and details a transaction (Sale of 1000 shares) by a person in a managerial responsibility position (Roland Berger, Member of an administrative or supervisory body) in Fresenius SE. This directly matches the definition for Director's Dealing (DIRS). The presence of section 15a of the WpHG further confirms this is a regulatory filing related to insider transactions.
2010-11-04 English
DGAP-DD: Fresenius SE english
Director's Dealing Classification · 100% confidence The document explicitly uses the header "Directors’ Dealings" and details a transaction (Sale) made by a person in a managerial position ("Roland Berger, Member of an administrative or supervisory body") concerning the company's ordinary shares. This directly matches the definition for Director's Dealing (DIRS). The reference to section 15a of the WpHG further confirms this is a regulatory filing concerning insider transactions.
2010-11-04 English
Fresenius SE: Fresenius reports excellent sales and earnings growth - raises outlook
Earnings Release Classification · 100% confidence The document is dated November 2, 2010, and explicitly states it is an 'Ad hoc announcement' reporting 'excellent sales and earnings growth' for the first three quarters (Q1-3/2010) and raising the outlook. It provides key financial metrics (sales, EBIT, net income) and compares them to the prior year period (Q1-3/2009). This structure—a brief announcement of period results with key figures and guidance changes—is characteristic of an Earnings Release (ER). It is not a full Annual Report (10-K) or a comprehensive Interim Report (IR), nor is it a transcript (CT) or a presentation (IP). Given the content focuses solely on the immediate release of period financial highlights, ER is the most appropriate classification. 9M 2010
2010-11-02 English
Analyst Conference Call - Q1-3/10 Results
Investor Presentation Classification · 95% confidence The document is titled "Analyst Conference Call – Q1-3/10 Results" and contains detailed financial tables, segment performance updates (Fresenius Kabi, Helios, Vamed), and a section on Cash Flow Development. The content is clearly structured for an investor audience following quarterly performance. This format, which includes key figures and segment commentary following a period's end, strongly indicates an Earnings Release (ER) or a document closely associated with it, such as a presentation accompanying the release. Since it contains detailed segment breakdowns and tables, it goes beyond a simple 'key highlights only' release, but it is not a full, comprehensive report like a 10-K or IR. However, the structure is typical of an earnings presentation or the detailed data often released alongside an Earnings Release. Given the explicit mention of 'Conference Call' and the presentation format, it is most likely the material used for the call, which is often classified as an Investor Presentation (IP) or sometimes grouped with the Earnings Release (ER) if it contains the primary results announcement. Since it presents the results themselves, ER is a strong candidate, but the structure suggests a presentation deck. Comparing ER (initial announcement, key highlights) vs IP (detailed presentation for investors), this document is highly detailed and structured like a presentation. I will classify it as an Investor Presentation (IP) because it is a structured presentation deck detailing the Q1-3/10 results, which is a common format for investor briefings.
2010-11-02 English

Browse filings by year

31 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.